Mitotane treatment for adrenocortical carcinoma: An overview

Minerva Endocrinologica

Volumn 37, Issue 1, 2012, Pages 9-23

  De Francia, S ^a   Ardito, A ^a   Daffara, F ^a   Zaggia, B ^a   Germano, A ^a   Berruti, A ^a   Di Carlo, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Adrenocortical carcinoma; Endocrine gland neoplasms; Mitotane, toxicity

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; GLYCOPROTEIN P; HYDROCORTISONE; MITOTANE; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE; SEX HORMONE BINDING GLOBULIN; TARIQUIDAR; THYROID HORMONE; VINCRISTINE;

ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ATAXIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONFUSION; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERANCE; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ENZYME INHIBITION; FOLLOW UP; GASTROINTESTINAL ABSORPTION; HUMAN; HYDROCORTISONE RELEASE; IN VITRO STUDY; LETHARGY; LIVER TOXICITY; LONG TERM CARE; LUNG METASTASIS; MAINTENANCE DRUG DOSE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR REGRESSION; VERTIGO; VOMITING;

ADRENAL CORTEX NEOPLASMS; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DELAYED DIAGNOSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INCIDENTAL FINDINGS; MALE; MITOTANE; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PRODRUGS; TREATMENT OUTCOME;

EID: 84860314125     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Grambach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA et al. Management of the clinically inapparent adrenal mass (" incidentaloma"). Ann Intern Med 2003; 138:424-9. (Pubitemid 36262654)
2. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309-40. (Pubitemid 38528713)
3. Terzolo M, Ali A, Osella G, Mazza E. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg 1997;132:914-9. (Pubitemid 27344146)
4. National-Cancer-Institute. Third national cancer survey: incidence data. DHEW Publ. No (NIH) 75-787. NCI monograph; 1975. p. 41.
5. Fassnacht M and Allolio B, unpublished observation.
6. Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004;22:838-45. (Pubitemid 41103595)
7. Pianovski MA, Maluf EM, de Carvalho DS, Ribeiro RC, Rodriguez-Galindo C, Boffetta P et al. Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil Pediatr Blood Cancer 2006;47:56-60. (Pubitemid 43787909)
8. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001;98:9330-5. (Pubitemid 32743916)
9. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711-36. (Pubitemid 30091090)
10. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008;113:3130-6.
11. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009;23:273-89.
12. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009;115:243-50.
13. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001;25:891-7. (Pubitemid 32666390)
14. Koschker AC, Fassnacht M, Hahner S, Weismann D, Allolio B. Adrenocortical carcinoma: improving patient care bv establishing new structures. Exp Clin Endocrinol Diabetes 2006;114:45-51.
15. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-2001.
16. Icard P, Louvel A, Chapuis Y. Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg 1992;16:753-8.
17. Using AW, Nam JM, Co Chien HT, McLaughlin JK, Fraumeni JF Jr. Risk factors for adrenal cancer: an exploratory study. Int J Cancer 1996;65:432-6.
18. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-55. (Pubitemid 23356754)
19. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-5. (Pubitemid 44024632)
20. Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001;136:543-9. (Pubitemid 32417544)
21. Schulick RD, Brennan MF. Adrenocortical carcinoma. World J Urol 1999;17:26-34.
22. Durusu M, Aksoy DY, Altundag MK, Abali H, Türker A, Cetin BE. Adrenal cortical carcinoma presenting initially with radius metastasis. Clin Oncol (R Coll Radiol) 2002;14:83-4.
23. Solans R, Vilardell M, Beatriz Vázquez A, Yagüe E. Bone metastases as presentation of adrenocortical carcinoma. Med Clin (Barc) 2001;116:76-7.
24. Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997;122:1212-8. (Pubitemid 28016693)
25. Haak HR, Hermans J, Van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;69:947-51. (Pubitemid 24140681)
26. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992;112:963-70.
27. Søreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 1992;16:663-7
28. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA. Adrenal cortical carcinoma. Cancer 1989;64:765-9. (Pubitemid 19185233)
29. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 2005;12:667-80. (Pubitemid 41483000)
30. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6:386-94. (Pubitemid 40561415)
31. MICROMEDEX Healthcare Series, Copyright© 1974-2009, Thomson Reuters.
32. Terzolo, unpublished observation.
33. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Brazilian J Med Biol Res 2000;33:1197-200.
34. Hart MM, Reagan RL, Adamson RH. The effect of isomers of DDD on the ACTH-induced steroid output, histology and ultrastucure of the dog adrenal cortex. Toxicol Appl Pharmacol 1973;24:127-59.
35. Nelson AA, Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1- dichloroethane (DDD or TDE). Arch Pathol (Chic) 1949;48:387-94.
36. Cueto C, Brown JH. The chemical fractionation of an adrenocorticolytic drug. Endocrinology 1958;62:326-33.
37. Nichols J, Hennigar G. Studies on DDD, 2,2-bis (parachlorophenyl)-1,1- dichloroethane. Exp Med Surg 1957;15:310-6.
38. Kaminsky N, Luse S, Hartroft P. Ultrastructure of adrenal cortex of the dog during treatment with DDD. J Natl Cancer Inst 1962;29:127-59.
39. Vilar O, Tullner WW. Effects of o,p'DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology 1959;65:80-6.
40. Bergenstal DM, Hertz R, Upsett MB, Moy RH. Chemiotherapy of Adrenocortical cancer with o,p'DDD. Ann Intern Med 1960;53:672-82.
41. Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma: clinical features in 138 patients. Am J Med 1966;41:572-80.
42. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973;223:1109-12.
43. Hoffman DL, Mattox VR. Treatment of adrenocortical carcinoma with o,p'-DDD. Med Clin North Am. 1972;56:999-1012.
44. Boven E, Vermorken JB, van Slooten H, Pinedo HM. Complete response of metastatized adrenal cortical carcinoma with op'-DDD. Case report and literature review. Cancer 1984;53:26-29. (Pubitemid 14215243)
45. WHO handbook for reporting results of cancer treatment. WHO Offset Pubblication No 48. Geneva, 1979.
46. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71:3119-23. (Pubitemid 23145548)
47. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001;25:914-26. (Pubitemid 32666394)
48. Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Baneriee TK et al. Eastern Cooperative Oncology Group study 1879:mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991;110:1006-13.
49. Haq MM, Legha SS, Saaman NA, Bodey GP, Burgess MA. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 1980;64:909-13. (Pubitemid 11139829)
50. Hajiar Ra, Hickey RC, Samaan NA. Adrenal cortical carcinoma:a study of 32 patients. Cancer 1975;35:549-54.
51. Hogan TF, Citrin DL, Johnson BM, Nakamura S, David TE, Borden EC. O,p'-DDD (mitotane) therapy for adrenal cortical carcionoma: observation on drug dosage, toxicity, and steroid replacement. Cancer 1978;42:2177-81.
52. Tattersall MH, Lander H, Bain B, Stocks AE, Woods RL, Fox RM et al. Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1980;1:419-21. (Pubitemid 10002849)
53. Grapski RT, Lopez JA, Krikorian JG, Melby JC. Cisplatin chemotherapy of adrenocortical carcinoma. Proc Am Soc Clin Oncol 1983;2:232.
54. Bodie B, Novick AC, Pontes JE, Straffon RA, Montie JE, Babiak T et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989;141:257-60. (Pubitemid 19061293)
55. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma:a Southwest Oncology Group Study. Cancer 2000;88:1159-65. (Pubitemid 30127678)
56. Van Slooten H, Moolenaar AJ, Van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p'-DDD:prognstic implications of serum level monitoring. Eur J of Cancer in Clin Oncol 1984;20:47-53. (Pubitemid 14224356)
57. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;92:1385-92. (Pubitemid 32947821)
58. Seki M, Nomura K, Hirohara D, Kanazawa M, Sawada T, Takasaki K et al. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. Endocr Relat Cancer 1999;6:529-33. (Pubitemid 30048462)
59. Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-37.
60. Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/Pglycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991;73:18-29. (Pubitemid 21901094)
61. Villa R, Orlandi L, Berruti A, Dogliotti L, Zaffaroni N. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 1999;14:133-8.
62. Abraham J, Bakke, S, Rutt A, Meadows B, Merino M, Alexander R et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94:2333-43. (Pubitemid 34457113)
63. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992;112:981-6. (Pubitemid 23008222)
64. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 1993;29:1036-8. (Pubitemid 23126709)
65. Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinomaa Southwest Oncology Group study. J Clin Oncol 1993;11:161-5. (Pubitemid 23059990)
66. Khan TS, Imam H, Juhlin C, Skogseid B, Gröndal S, Tibblin S et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11:1281-7.
67. Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 1998;78:546-9. (Pubitemid 28360647)
68. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998;83:2194-200. (Pubitemid 28525402)
69. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma:a large prospective phase II trial. Endocr Relat Cancer 2005;12:657-66. (Pubitemid 41482999)
70. Sperone P, Berruti A, Gorzegno G, Paccotti P, Terzolo M, Porpiglia F et al. Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane. J Endocrinol Invest 2006;29:560-2. (Pubitemid 44164899)
71. Fox E, Bates SE. Tariquidar (XR9576):a P-glycoprotein drag efflux pump inhibitor. Expert Rev Anticancer Ther 2007;7:447-59. (Pubitemid 46681800)
72. Menefee ME, Huang H, Edgerly M, Kotz H, Merino M, Balis FM et al. Effects of the P-glycoprotein (MDR1) antagonist tariquidar (XR-9576;TQD) on MDR1 function as well as the toxicity and efficacy of combined chemotherapy in patients with metastatic adrenocortical cancer (mACC). J Clin Oncol 2008;26 (20 suppl):abstr 2543.
73. Faggiano A, Leboulleux S, Young J, Schlumberger M, Baudin E. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol 2006;64:110-3.
74. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrin Metab 2000;86:2234-8. (Pubitemid 32269248)
75. De Francia, unpublished observation.
76. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer, 2008;15:1043-53.
77. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol 1989;31:51-7. (Pubitemid 19178144)
78. Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Brazilian J Med Biol Res 2000;33:1191-6.
79. Nader N, Raverot G, Emptoz-Bonneton A, Déchaud H, Bonnay M, Baudin E. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab 2006;91:2165-70. (Pubitemid 43855000)
80. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011;96:1844-51.
81. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clinical Endocrinology 2004;60:273-87. (Pubitemid 38297116)
82. Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C. Adrenocortical carcinoma in surgically treated patients:a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992;112:972-80. (Pubitemid 23008221)
83. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995;75:2587-91.
84. Dickstein G, Shechner C, Arad E, Best LA, Nativ O. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998;83:3100-03. (Pubitemid 28500941)
85. Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg 1982;117:1142-6. (Pubitemid 12009751)
86. Barzon L, Fallo F, Sonino N, Daniele O, Boscaro M. Adrenocortical carcinoma: experience in 45 patients. Oncology 1997;54:490-6. (Pubitemid 27470260)
87. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J of Med 2007;2372-80. (Pubitemid 46883771)
88. Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma. Letter to the Editor. N Engl J Med 2007;357:1256-57. (Pubitemid 47443196)
89. Schteingart DE. Adjuvant mitotane therapy of adrenal cancer-use and controversy. N Engl J Med 2007;356:2415-8. (Pubitemid 46883778)
90. Lee JE. Adjuvant mitotane in adrenocortical carcinoma. Letter to the Editor. N Engl J Med 2007;357:1256-58.
91. Stojadinovíc A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941-50. (Pubitemid 34141836)